{"nctId":"NCT00798707","briefTitle":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder","startDateStruct":{"date":"2008-12"},"conditions":["Major Depressive Disorder"],"count":709,"armGroups":[{"label":"Desvenlafaxine succinate sustained-release 25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)"]},{"label":"Desvenlafaxine succinate sustained-release 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Desvenlafaxine Succinate Sustained-Release (DVS SR)","otherNames":[]},{"name":"Desvenlafaxine Succinate Sustained-Release (DVS SR)","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)\n* Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \\>= 20\n* Clinical Global Impressions Scale-Severity (CGI-S) score of \\>= 4\n\nExclusion Criteria:\n\n* Clinical instability - 25% or greater increase/decrease in HAM-D 17 total score from screening to baseline\n* Significant risk of suicide as assessed by clinician judgement, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET)","description":"HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.52","spread":"0.44"},{"groupId":"OG001","value":"-8.98","spread":"0.44"},{"groupId":"OG002","value":"-10.02","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)","description":"CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)","description":"CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":"0.07"},{"groupId":"OG001","value":"-1.22","spread":"0.07"},{"groupId":"OG002","value":"-1.24","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)","description":"MADRS measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.23","spread":"0.61"},{"groupId":"OG001","value":"-10.23","spread":"0.60"},{"groupId":"OG002","value":"-11.29","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)","description":"HAM-D6: a standardized, clinician-administered rating scale that assesses 6 items characteristically associated with major depression and is a subset of HAM-D17. HAM-D6 score ranges from 0-22. The scale uses HAM-D17 items: 1, 2, 7, 8, 10 and 13. Item 13 is scored 0-2 and all others are scored 0-4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.94","spread":"0.26"},{"groupId":"OG001","value":"-5.03","spread":"0.26"},{"groupId":"OG002","value":"-5.65","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)","description":"A HAM-D17 responder was defined as a participant with a 50% or greater decrease from baseline in HAM-D17 score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)","description":"Remission was defined as a HAM-D17 score of less than or equal to 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)","description":"A MADRS responder was defined as a participant with a 50% or greater decrease from baseline in MADRS score. It measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)","description":"CGI-I responder was defined as a participant with a score of 1 (very much improved) or 2 (much improved) on the CGI-I. CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Population Pharmacokinetics for Desvenlafaxine Plasma Concentrations","description":"Relationship of demographic variables (age, gender, food, race, creatinine, aspartate aminotransaminase, alanine transaminase, bilirubin and concomitant medications) were examined by fitting measured DVS plasma concentrations to a 1 compartment model with first order absorption. Demographic variables were examined for clearance (CL/F), volume of distribution (V/F), Steady Area under Curve (AUC) using nonlinear mixed effects modeling. Final parameter estimates for demographic factors effecting CL/F, V/F and AUC were determined.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in SDS at FOT Evaluation (Week 8 or ET)","description":"SDS: a self-administered tool that measures functional impairment in 3 domains: Work/School, Social Life, and Family Life/Home Responsibilities. The participant rates the extent to which each of these domains is impaired by his/her symptoms using a 10 point visual analog scale: (0=not at all impaired, 10=extremely impaired) for a total maximum score of 30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.17","spread":"0.43"},{"groupId":"OG001","value":"-3.26","spread":"0.43"},{"groupId":"OG002","value":"-3.23","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"0.16"},{"groupId":"OG001","value":"-1.07","spread":"0.15"},{"groupId":"OG002","value":"-1.12","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":"0.16"},{"groupId":"OG001","value":"-1.26","spread":"0.15"},{"groupId":"OG002","value":"-1.21","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.88"},{"groupId":"OG001","value":"-1.83","spread":"2.12"},{"groupId":"OG002","value":"-0.97","spread":"0.89"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in WHO-5 Total Score at FOT Evaluation (Week 8 or ET)","description":"WHO-5 evaluates positive psychological well-being. WHO-5 consists of 5 questions and each is rated on a 6-point scale. The total score ranges from 0 to 25 (0= worst possible quality of life; 25=best possible quality of life).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":"0.31"},{"groupId":"OG001","value":"3.43","spread":"0.31"},{"groupId":"OG002","value":"3.25","spread":"0.31"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Sexual Dysfunction at FOT Evaluation (Week 8 or ET)","description":"ASEX scale includes 5 questions that evaluate sexual function exclusively during the week prior to completion in the following areas: libido, excitability and ability to reach orgasm. Sexual dysfunction=an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. Participants who have had no sexual activity during the prior week should be instructed to not complete questions 3 through 5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"52.7","spread":null},{"groupId":"OG002","value":"55.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Categorical Scores on the C-SSRS at FOT Evaluation (Week 8 or ET)","description":"C-SSRS mapped into C-CASA(1-7) to assess whether participant:completed suicide(1),suicide attempt(2)(response of \"Yes\" on \"Actual Attempt\"),preparatory acts toward imminent suicidal behavior (3)(\"Yes\" on \"Preparatory Acts or Behavior\"),suicidal ideation (4)(\"Yes\" on \"Wish to be dead\",\"Non-Specific Active Suicidal Thoughts\",\"Active Suicidal Ideation with methods without Intent to Act or Some Intent to Act,without Specific Plan or with Specific Plan and Intent),any suicidal behavior or ideation,self-injurious behaviour(7)(\"Yes\" on \"Has subject engaged in Non-suicidal Self-Injurious Behavior\").","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Discontinuation-Emergent Signs and Symptoms (DESS) Total Score","description":"DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of \"new symptoms\" and \"old (but worse) symptoms\" (1) and 0 for \"old and unchanged symptom,\" \"absent,\" or \"old symptom but improved\" for a total possible range of 0 to 43. A higher score indicates more symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"1.62"},{"groupId":"OG001","value":"0.63","spread":"1.30"},{"groupId":"OG002","value":"0.62","spread":"1.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"2.68"},{"groupId":"OG001","value":"1.38","spread":"2.58"},{"groupId":"OG002","value":"1.50","spread":"2.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"2.28"},{"groupId":"OG001","value":"0.74","spread":"1.23"},{"groupId":"OG002","value":"0.63","spread":"1.60"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":231},"commonTop":["Nasopharyngitis","Headache","Nausea","Dizziness","Diarrhoea"]}}}